ravive, Inc. (NASDAQ:ARAV, ", the Company", ))))), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the presentation of updated results from its ongoing Phase 1b/2 trial of batiraxcept in clear cell renal cell carcinoma (ccRCC) at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place February 16-18, 2023 in San Francisco and virtually. The poster presentation will highlight updated results from the Phase 1b portion of the trial in 26 patients with advanced or metastatic ccRCC who have progressed after 1 or 2 prior lines of immuno-oncology (IO)- and vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI)-based therapies.
Palo Alto Networks Stock Is Rising: What’s Going On?
Palo Alto Networks (NASDAQ: PANW) is stirring up investor interest with notable movement in its stock price. Anticipation is building as the company prepares to release its third-quarter fiscal 2024 earnings on May 20.
